Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
ISRG — frequently asked questions
Is Intuitive Surgical Inc. overvalued?
In our latest published analysis dated 2026-09-26, ISRG looks meaningfully overvalued. The price recorded at analysis is USD 405 versus our fair value of USD 196; the high endpoint is presented separately as potential value of USD 235. That implies roughly 51.7% downside to fair value at that date.
Our latest published report, analyzed 2026-09-26, gives ISRG a fair value of USD 196 and a potential value of USD 235. The conclusion is triangulated across multiple valuation models and weighted by reliability for Intuitive Surgical Inc.'s archetype; it is a dated research output, not a live price.
Should I buy ISRG now?
Our latest published rating for ISRG, analyzed 2026-09-26, is Sell. Intuitive Surgical Inc. looks meaningfully overvalued at the analysis-date price of USD 405 versus fair value of USD 196; potential value is USD 235. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for ISRG?
The dedicated bear-case section in our report analyzed 2026-09-26 documents Intuitive Surgical Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is ISRG's rating?
Our latest published rating for ISRG, analyzed 2026-09-26, is Sell, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 196, the potential value of USD 235, and the price recorded at analysis (USD 405).
Accelerated da Vinci 5 adoption and software feature additions, combined with rapid penetration of outpatient ambulatory surgical centers and cost-sensitive international markets via the XiR platform, could drive procedure growth above 17% and expand potential equity value toward our Potential value of USD 235.14 per share.
สิ่งที่จะเปลี่ยนมุมมองของเรา
Hospital capital budget tightening causing US system placements to remain predominantly replacement trade-ins with systems revenue declining more than 5% year-over-year.
We rate Intuitive Surgical Inc. Sell with a Fair value of USD 195.88, as the report-date price of USD 405.18 on September 25, 2026 trades at an excessive premium to the company's long-term fundamental earnings power.3
The house rating is Sell. For an ordinary investor, this means the stock does not offer an attractive risk-adjusted return at this price, and investors should look to trim or avoid positions to protect capital.
The report was prepared at a price of USD 405.18 on September 25, 2026. This price stands 106.9% above our Fair value of USD 195.88, indicating 51.7% downside to intrinsic value. The report-date price also sits 72.3% above our Potential value of USD 235.14, which reflects an optimistic operating case where da Vinci 5 adoption and international penetration accelerate.
The main risk that would trigger further fundamental deterioration is a freeze in hospital capital spending paired with saturation of US replacement trade-ins. Because trade-ins do not expand the installed base, hospital budget pressures could cause systems revenue (USD 2,473.7 million in FY2025) to contract. If this slowdown coincides with the H1 2027 rollout of extended-use instruments that dilutes recurring consumable sales per procedure while operating expenses rise 13%, operating margins would compress well below 26.5% and cause a sharp multiple derating.3,4,7
The main reason the business creates long-term value is its wide economic moat in robotic soft-tissue surgery. High surgeon switching costs and hospital workflow integration ensure that system placements generate steady, high-margin sales of instruments and accessories, which reached USD 6,018.9 million in FY2025. This recurring razor-and-blade model produces substantial free cash flow (USD 2,490.7 million in FY2025), but even under our Potential value scenario of USD 235.14, the report-date market price remains detached from fundamental economics.5,7
Dominant Robotic Ecosystem and Switching Costs
Intuitive maintains deep operational integration and surgeon credentialing across global operating rooms, securing USD 6,018.9 million in recurring instrument and accessory revenue in FY2025.7
da Vinci 5 Technological Advantage
The newly introduced da Vinci 5 architecture provides 10,000x compute capability, enabling regular digital and software enhancements that deepen hospital clinical entrenchment.4
International and Value-Tier Runway
Adoption of the cost-effective XiR platform across 11 to 12 countries addresses price-sensitive public healthcare systems, providing long-term procedural expansion runway beyond the United States.4
ข้อแนะนำของบริษัท
Intuitive Surgical is rated Sell because its report-date market price of USD 405.18 trades at more than double our Fair value of USD 195.88, creating severe valuation risk despite the company's high-quality robotic surgery moat.3
ภาพรวมบริษัท
Intuitive Learning is its customer learning management system that empowers customers to complete technology and procedure education, while also being able to view, assign, and track technology and simulation learning. Intuitive Learning provides professional education for surgeons/physicians, residents/fellows, care teams, patient side assists, robotic coordinators, and sterile reprocessing staff.
In the U.S. (for some government customers), China, and Japan, the company also utilizes certain distributors in addition to its direct sales organizations. In the remainder of its OUS markets, the company provides its products for sale through distributors.
§2 กรณีลบEN
A rigorous fundamental stress test evaluates the vulnerability of Intuitive Surgical's valuation when confronting concurrent operational and macroeconomic headwinds. The primary vulnerability is not balance sheet distress—given zero total debt and $3,368,000,000 in cash —but rather severe valuation multiple derating caused by procedural and margin deceleration. At the analysis price of $405.18, ISRG trades at 33.33x forward P/E, pricing in uninterrupted multi-year growth. If hospital capital budgets contract and US placements remain dominated by trade-ins, systems revenue of $2,473,700,000 contracts by 5% annually. Concurrently, if the H1 2027 rollout of extended-use EndoWrist instruments dilutes consumable revenue per case across the $6,018,900,000 I&A segment while operating expenses rise 13% YoY, operating margins compress toward 26.5% rather than reaching the projected 30.0% level. Compounding these domestic pressures with centralized procurement delays in China and Japan reduces consolidated 5-year revenue growth from consensus double digits toward single digits. Under this confluence of shocks, market multiples would compress from 33.33x toward the medtech peer median of 18.15x, collapsing intrinsic valuation toward the lower boundary of $151.10, generating over 50% downside from current market quotes.
Hospital capital budget constraints induce multi-year system placement contraction
Domestic da Vinci trade-in saturation curtails net installed base capacity additions
Extended-use instrument cycles dilute consumable revenue per surgical case
วิธีที่ธีสิสนี้อาจล้มเหลว
Hospital capital budget tightening and da Vinci 5 trade-in saturation induce multi-year system placement contraction
Management noted that US placements in Q2 2026 were predominantly trade-ins that do not expand the installed base, while installed base expansion has moderated. Systems revenue of $2,473,700,000 in FY2025 would contract if hospital capital budgets freeze, reducing consolidated growth and triggering negative revisions as modeled in forward_earnings.4,7
FV impact
-4.7%
The analyst's bear scenario path and multiple as the base case
Trigger
Within 12 months
สัญญาณเตือนล่วงหน้าที่ต้องเฝ้าระวัง
ห้าพัฒนาการที่อาจทำให้กรณีการลงทุนของเราอ่อนแอลง
01
da Vinci Procedure Volume Growth YoY
Deceleration below double-digit procedural expansion directly undermines utilization and consumable revenue flow-through across the $6.02B I&A segment.
Intuitive Surgical commands a wide economic moat that is among the most formidable in the medical technology sector. The company's competitive advantage is anchored not merely by high-end robotic hardware, but by an integrated surgical ecosystem comprising proprietary instrumentation, clinical workflow integration, and comprehensive surgeon training. Having pioneered robotic-assisted minimally invasive surgery over two decades ago, Intuitive has established deep institutional roots within hospital operating rooms globally. Surgeons spend hundreds of hours training on da Vinci consoles during residencies and fellowships, developing muscle memory and procedural familiarity that make switching to rival robotic platforms both clinically risky and economically inefficient.
The financial manifestation of this moat is a resilient razor-and-blade business model where high-margin recurring revenues dominate consolidated results. In FY2025, instruments and accessories generated $6,018,900,000, accounting for 59.8% of total revenue ($10,064,700,000), while service contracts contributed an additional $1,572,100,000. Combined, recurring streams represent approximately 75% of total business. Once an operating room installs a da Vinci system, each completed procedure generates predictable consumable sales with gross margins near 68%–69%. Even as domestic system placement growth moderates toward replacement cycles, US system utilization expanded 3% in Q2 2026, corroborating steady operational compounding.
While general medtech peers such as Align Technology, Cooper Companies, and Thermo Fisher operate in adjacent healthcare categories, none compete directly in multi-port soft-tissue robotic surgery. Prospective entrants face multi-year barriers to entry including regulatory clearances, extensive clinical trial validation, and hospital credentialing committees. However, Intuitive's moat is not entirely immune to economic friction. In domestic markets, Q2 2026 system placements were predominantly trade-in upgrades rather than net new installed base expansion, while management's initiative to increase uses per EndoWrist instrument in H1 2027 threatens to lower consumable revenue per case. Internationally, foreign revenue of $3,248,900,000 faces pricing scrutiny in China and funding delays in Japan. These structural dynamics do not erode Intuitive's wide moat rating, but they bound near-term procedural monetization.
กำไรเชิงเศรษฐกิจ
Intuitive Surgical generates substantial economic profit, with returns on invested capital of ~15% comfortably exceeding its computed cost of capital (WACC of 10.23% as of 2026-09-26), passing the return-on-capital hurdle and justifying a 15-year moat duration. In FY2025, operating income reached $2,945,500,000 on consolidated revenue of $10,064,700,000, generating an operating margin of 29.27% that dwarfs the broader healthcare industry benchmark of 15.5%.1,6
9/ 10
Wide
Sources of advantage
01High surgeon switching costs and hospital workflow entrenchment — Over two decades of surgeon training, residency curriculum integration, and nursing staff credentialing create insurmountable switching costs. In FY2025, recurring instruments and accessories revenue reached $6,018,900,000, representing 59.8% of total revenue ($10,064,700,000). High system utilization (US utilization up 3% in Q2 2026) reinforces operating room entrenchment.Wide
02Proprietary robotic platform architecture and intellectual property — Intuitive possesses an unmatched patent estate and advanced computing platform. The da Vinci 5 platform introduces ten-thousand-fold compute capability enabling continuous software updates and digital ecosystem enhancements, while tiered offerings across da Vinci 5, Xi, and XiR insulate the platform across academic medical centers and outpatient surgery centers.Wide
ภัยคุกคามที่รู้ต่อความได้เปรียบ
ภัยคุกคาม
ความรุนแรง
ไทม์ไลน์
การบรรเทา
Hospital capital budget tightening and da Vinci 5 trade-in saturation
medium
12 to 24 months
Intuitive deploys flexible acquisition models including operating leases and usage-based arrangements, alongside tiered platforms like the XiR system to accommodate constrained hospital capital cycles.4
The highlighted cell is Fair value when every assumption sits at its base level ($195.88). Each row and column shows what Fair value becomes when one assumption moves.
In the Base scenario, representing the modal fundamental trajectory, Intuitive sustains steady procedural compounding consistent with corporate guidance. System placements in mature domestic markets tilt heavily toward trade-in upgrades rather than greenfield additions, while international expansion through tiered offerings partially balances public healthcare reimbursement delays. Normalized cash flows and cost of equity discounting yield a Base scenario target of $195.88 with a probability of 60.0% and an expected return of -51.7% against $405.18, aligning closely with the house Fair value of $195.88. This path would be disconfirmed by a sudden procedural volume contraction below double digits or by rapid multiple compression toward medtech peer medians.
da Vinci placement cadence exceeds historical upgrade cycles across domestic hospitals and ambulatory surgical centers
International procedural adoption in Europe and Asia outpaces domestic growth rates
Consolidated operating margins expand beyond historical highs driven by software updates and manufacturing scale
§7 ต้นไม้การตัดสินใจผลประกอบการEN
ดีกว่าคาด
Maintain Sell; Re-examine placement mix between trade-in upgrades and greenfield additions, monitor instrument utilization rates, and maintain the existing disciplined stance without chasing operational beats at elevated multiples.
ทริกเกอร์: Consolidated revenue and procedure growth exceeding the upper boundary of full-year guidance with operating margin expanding above historical levels
A quarterly beat driven by higher procedural volume and rapid da Vinci adoption would reaffirm company operating quality, but because the shares trade at $405.18—well above Fair value of $195.88 and Potential value of $235.14—the valuation remains extended and upside is -51.7%, warranting maintaining Sell.
ตามคาด
Maintain Sell; Track trade-in cadence across domestic hospitals and review international placement trends across European and Asian accounts while maintaining existing portfolio allocation.
ทริกเกอร์: Procedure growth tracking the midpoint of annual guidance alongside non-GAAP gross margin within guided ranges
Inline operating execution confirms the established compounding trajectory but fails to justify the significant premium over healthcare peers, leaving the shares fundamentally overvalued against Fair value of $195.88.
ต่ำกว่าคาด
Maintain Sell; Assess procedure deferrals across benign surgical categories, verify tender timing in key international markets, and confirm portfolio hedges.
ทริกเกอร์: Procedure growth falling below guided annual ranges accompanied by system placement contraction or operating margin compression
A quarterly shortfall would expose the fragility of the elevated multiple, accelerating multiple contraction toward peer medians as growth decelerates.
คุณภาพกำไร
High earnings quality is underpinned by excellent cash conversion, where operating cash flow consistently exceeds net income. Working capital management remains disciplined, receivables and inventory turns reflect steady procedural pull-through, and the absence of debt provides financial flexibility. The primary structural variance between reported net earnings and cash flow remains noncash stock-based compensation, which management guides to expand alongside company scale.
ตัวชี้วัดที่ต้องเฝ้าก่อนการประกาศ
01
ตัวชี้วัด:
da Vinci Procedure Volume Growth
ปัจจุบันManagement reiterated full-year procedure growth guidance within historical double-digit expectations.
ทำไมจึงสำคัญ
Procedure expansion drives utilization and instrument consumption, directly setting the pace of recurring revenue and cash generation.
02
ตัวชี้วัด:
System Placements and Installed Base Mix
ปัจจุบันRecent domestic placements were predominantly trade-in upgrades rather than net new installations, resulting in moderating installed base growth.
Intuitive Surgical exhibits stellar cash flow generation, reflecting the cash-generative nature of its recurring business model. In FY2025, operating cash flow reached $3,030,500,000, delivering an exceptional 106.1% cash conversion ratio relative to GAAP net income of $2,856,000,000. Capital expenditures totaled $539,800,000 (5.36% of revenue), yielding free cash flow of $2,490,700,000. Noncash stock-based compensation totaled $788,200,000 in FY2025, with management guiding FY2026 stock compensation between $880,000,000 and $900,000,000. Free cash flow conversion remains pristine, fully funding internal capacity additions and operational expansion without debt reliance.
Intuitive Surgical demonstrates exceptional, moat-protected capital productivity. Returns on invested capital of ~15% have remained highly stable across multi-year product cycles, driven by high gross margins (68%-69% guided non-GAAP for FY2026) and an asset-light consumable business model where instruments and accessories generate 59.8% of consolidated sales ($6,018,900,000 in FY2025).
Intuitive's return on invested capital of ~15% comfortably surpasses its cost of capital (WACC of 10.23% as of 2026-09-26), driven by zero debt and a cost of equity of 10.24%. This positive economic spread verifies the company's wide economic moat.
Razor-and-blade consumable recurring revenue delivers immense cash flow visibility and high margin durability.
Intuitive Surgical Inc. (ISRG) trades at 33.3x forward earnings against a peer median of 18.2x. Its EV/EBITDA of 33.0x compares with a peer median of 19.3x. The comparison uses 4 peers: Vertex Pharmaceuticals Incorporated, Thermo Fisher Scientific Inc., Align Technology Inc. and The Cooper Companies Inc., as of 2026-09-26.
§10 อุตสาหกรรมและวัฏจักรEN
ระยะของวัฏจักร
Expansion
ISRG capital expenditures of $539,800,000 in FY2025 represented 5.36% of revenue ($10,064,700,000), tracking slightly above the healthcare product industry benchmark capex-to-revenue ratio of 4.5%. Intuitive's capex-to-depreciation ratio stands at 0.80 ($539.8M capex vs $677.1M depreciation), exactly matching the industry benchmark ratio of 0.80. Capacity expansion is directed toward da Vinci 5 manufacturing facilities and digital infrastructure. However, because comprehensive industry-wide lead-time, customer-concentration, and competitor capacity figures are not disclosed in available evidence, this capital cycle assessment is demand-led and evidence-limited.6
วัฏจักรขาขึ้น
The bull cycle for surgical robotics is propelled by ongoing global adoption of minimally invasive robotic-assisted surgery across general surgery, thoracic, gynecology, colorectal, and urological procedures. The commercialization of next-generation platforms like the da Vinci 5, featuring advanced digital architecture and sensing capabilities, accelerates system replacement cycles across Tier-1 medical institutions. Concurrently, outpatient migration creates greenfield expansion opportunities in ambulatory surgical centers and hospital outpatient facilities, while developing international markets offer decades of procedural penetration runway.
วัฏจักรขาลง
The bear cycle materializes when macroeconomic tightening and elevated interest rates force hospital finance committees to defer capital equipment expenditures and extend the operational life of existing robotic systems. As domestic market penetration reaches maturity, placements transition almost entirely to replacement trade-ins rather than net capacity additions. Concurrently, government-mandated price concessions in key Asian markets and centralized tender frameworks suppress international hardware margins, while cost-containment efforts by hospital procurement departments pressure consumable instrument pricing per case.
แนวโน้มระยะยาว
แนวโน้ม
ผลกระทบ
หมายเหตุ
Surgical transition from open and laparoscopic procedures to robotic-assisted minimally invasive surgery
positive
Robotic platforms deliver improved 3D visualization, tremor filtration, and instrument articulation, reducing hospital length of stay, complications, and patient recovery times, sustaining long-term double-digit procedure growth (13.5%–15.5% guided in FY2026).
Surgical procedure migration to ambulatory surgical centers and outpatient settings
positive
Health systems increasingly migrate high-volume benign procedures to lower-cost outpatient settings, accelerating demand for flexible capital configurations like the XiR system, which represented 20 of 27 ASC placements in Q2 2026.
การวางตำแหน่ง
Intuitive Surgical occupies the unchallenged premier leadership position in global soft-tissue robotic surgery. Its consolidated FY2025 revenue of $10,064,700,000 and operating profit of $2,945,500,000 (29.27% operating margin) demonstrate exceptional scale advantage over medtech peers like Align Technology (18.25% margin) and Cooper Companies (20.82% margin). By offering a multi-tiered portfolio (da Vinci 5, Xi, and XiR), Intuitive successfully addresses both premium academic hospitals and cost-sensitive regional healthcare providers globally.6
§11 การจัดการสถานะEN
การกำหนดขนาด
With a Sell rating and shares trading at $405.18 as of 2026-09-25 against a synthesized Fair value of $195.88 (representing 106.85% premium to fair value and -51.66% upside), no capital allocation is warranted. Investors holding positions should systematically exit or trim exposure.3
ความเสี่ยง
Risk management for Intuitive Surgical centers on avoiding capital loss driven by valuation de-rating rather than balance sheet distress. The company maintains zero total debt and holds $3,368,000,000 in cash, precluding solvency risk. However, trading at 33.33x forward P/E against peer healthcare medtech multiples near 18.15x exposes investors to severe valuation risk. Portfolio managers should enforce strict stop-loss rules, avoid averaging down, and utilize call writing or hedging strategies to safeguard capital while the market's growth expectations normalize.
Accelerate position exit as procedural slowdown falsifies compounding thesis and compresses multiple
US Installed Base Net Additions
< 0 net new units per quarter (100% trade-in replacement)
Reduce long-term procedural revenue growth assumptions to reflect market saturation
§12 มุมมองนักลงทุนEN
Value Investor
Avoid
At USD 405.18 on September 25, 2026, Intuitive Surgical trades at 33.33x forward earnings, an 83.6% premium to the medtech peer median forward P/E of 18.15x. The price sits 106.9% above our Fair value of USD 195.88, offering zero margin of safety.3
Growth Compounder
Avoid
Although 2026 procedure volume is guided to grow 13.5% to 15.5% and FY2025 revenue reached USD 10,064.7 million, US system placements are predominantly replacement trade-ins rather than net-new additions. Even under our optimistic Potential value scenario of USD 235.14, the stock remains overvalued by 42.0%.4,6
Institutional Core
Avoid
Holding ISRG at current multiples exposes institutional capital to severe derating risk if hospital capital budgets freeze or if the H1 2027 rollout of extended-use instruments reduces consumable revenue per procedure. Reallocating exposure toward reasonably priced healthcare compounders preserves risk-adjusted capital.4
§14 ข้อแนะนำสุดท้ายEN
การกระทำ
ขาย
We recommend a Sell rating on Intuitive Surgical Inc. based on a Fair value of USD 195.88 per share, representing 51.7% downside from the report-date price of USD 405.18 on September 25, 2026. Intuitive commands an exceptional wide economic moat in robotic-assisted surgery, but current market pricing at 33.33x forward earnings reflects extreme optimism that discounts growth far beyond justifiable fundamental cash generation.3
Even in our high-end Potential value scenario of USD 235.14, the stock remains overvalued by 42.0%. With US placements increasingly dominated by trade-ins rather than installed base expansion and upcoming extended-use instrument cycles threatening consumable realization in H1 2027, the risk-reward skew is decisively unfavorable.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
In the downside scenario, hospital capital budget tightening and saturation of domestic trade-in demand restrict system placements, while extended hospital review cycles and healthcare budget constraints in foreign markets restrain international volume. Concurrently, the rollout of extended-use instruments reduces consumable revenue per procedure while operating expenses remain elevated, compressing operating margins. Under these compounding pressures, fundamental earnings power contracts and the market multiple de-rates toward peer medians. Investors would observe early confirmation through negative system placement growth, gross margin slippage, and downward revisions to outer-year consensus projections.
Terminal exit multiple compresses toward healthcare medtech peer median upon growth normalization
ISRG trades at 33.33x forward P/E against peer median forward P/E of 18.15x (ALGN 11.7x, COO 11.8x, TMO 24.5x, VRTX 26.2x). As revenue growth fades toward 8.0% by FY2030, multiple compression to 20.0x reduces forward earnings fair value by 20%.2,3
Management plans to increase uses on subset of EndoWrist instruments in H1 2027 to lower customer procedure costs, threatening recurring I&A revenue ($6,018,900,000). Coupled with 13% non-GAAP opex growth and gross margin slipping from 67.46% to 66.00%, operating margin drops below 26.5%, well below the assumed 30.0% path.4,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 18 months
International tender gridlock and pricing concessions across China and Japan drag 5-year procedural growth
Foreign revenue represents $3,248,900,000. Management noted China is competitive and challenging on pricing, while Japan has faced government funding delays. A systemic tender slowdown in key Asian markets combined with US trade-in saturation depresses 5-year top-line growth by ~10 percentage points below consensus.4,7
FV impact
-4.1%
Revenue and EPS growth 10 points lower for five years
EndoWrist extended-use cycles in H1 2027 paired with 13% opex growth compress operating profitability well below the 30.0% normalized assumption.
ปัจจุบัน:29.27% (FY2025 GAAP)
แจ้งเตือนหาก< 26.5%
03
Global installed base and clinical training network effects — Intuitive's extensive global installed base creates institutional lock-in, with foreign revenue reaching $3,248,900,000 in FY2025. Deployment of the XiR system has already reached 11 to 12 countries, facilitating international procedural expansion despite centralized public procurement constraints.
Moderate
EndoWrist extended-use cycle rollout diluting consumable revenue per procedure
medium
12 to 18 months
Management aims to stimulate procedural volume expansion in benign surgical categories and cost-sensitive geographies to offset the per-procedure consumable realization impact.4
International tender gridlock and pricing concessions across Asian healthcare systems
medium
18 to 36 months
Deployment of the value-oriented XiR system across price-sensitive healthcare systems and positive reimbursement decisions enacted in Japan in June 2026 support volume recovery.4
35.1%
Method
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
How this lens was calculated
Inputs used in this report
Terminal exit multiple remains resilient at elevated levels reflecting premium medtech moat status
In the Bull scenario, accelerated da Vinci replacement cycles across domestic hospitals and rapid uptake in outpatient ambulatory surgical centers, combined with faster procedural penetration in underpenetrated international markets via the value-tier platform, drive procedural expansion above guided ranges. Under this trajectory, fundamental earnings power supports a scenario target of $235.14 with an estimated scenario probability of 20.0% and an expected return of -42.0% relative to $405.18. This outcome requires uninterrupted hospital capital budgets, seamless digital ecosystem software monetization, and prompt resolution of overseas tender backlogs. The scenario would be disconfirmed if hospital capital freezes or if pricing pressure in Asian accounts dampens international placement velocity.
ทำไมจึงสำคัญ
Net installed base additions expand future consumable demand, whereas a high proportion of trade-ins caps long-term procedural capacity.
03
ตัวชี้วัด:
EndoWrist Extended-Use Rollout Timing
ปัจจุบันEngineering deployment is slated for the first half of next fiscal year with progressive financial effects across benign procedures.
ทำไมจึงสำคัญ
Increasing uses per instrument lowers hospital procedure cost to unlock benign surgical volumes, but risks cannibalizing recurring instrument revenue per case.
ปัจจุบันManagement raised non-GAAP gross marginguidance for the full year, reflecting operational leverage and product cost discipline.
ทำไมจึงสำคัญ
Gross margin flow-through funds elevated research and manufacturing investments while sustaining high operating profitability.
05
ตัวชี้วัด:
International Tender Execution and Reimbursement
ปัจจุบันTender restructuring in China and funding delays in Japan face offset from value-tier system adoption and updated Japanese reimbursement schedules.
ทำไมจึงสำคัญ
Expanding outside the domestic market is required to sustain long-term compound growth as domestic installed base growth moderates.
Management exercises disciplined capital stewardship, maintaining a fortress balance sheet characterized by zero total debt as of 2026-09-26 and $3,368,000,000 in cash and equivalents at year-end FY2025. With no dividend program, capital allocation is concentrated on organic growth investments and advanced platform engineering. Diluted share count has been prudently managed: 357,400,000 in FY2023, 362,000,000 in FY2024, and 362,700,000 in FY2025, with shares outstanding standing at 358,278,000 as of 2026-09-26.
In FY2025, recurring instruments and accessories revenue reached $6,018,900,000 (59.8% of $10,064,700,000 total revenue), while service revenue generated $1,572,100,000. Combined recurring revenue exceeded 75% of sales, supported by 3% US utilization growth in Q2 2026.
Procedural expansion insulates core cash generation from quarterly lumpiness in capital system sales, creating a resilient economic buffer during hospital budget freezes.
Operating expense inflation and extended-use instrument cycles will challenge operating margin expansion toward the modeled 30.0% level.
Non-GAAP operating expenses increased 13% YoY in Q2 2026 driven by manufacturing headcount and facility expansions, while management announced plans to expand uses per EndoWrist instrument in H1 2027 to lower procedure costs in cost-sensitive procedures.
Increasing uses per instrument dilutes consumable revenue per case across the $6.02B I&A segment, requiring substantial procedural volume acceleration to avoid operating margin compression.
Severe disconnect between fundamental intrinsic value and prevailing market multiples creates extreme downside risk.
At $405.18 as of 2026-09-25, ISRG trades at 33.33x forward P/E, compared to peer median forward P/E of 18.15x (ALGN 11.7x, COO 11.8x, TMO 24.5x, VRTX 26.2x). Diagnostic reverse DCF indicates the market implies 10-year growth of 24.96%, a 6.69 percentage point gap over fundamental growth of 18.27%.
Even with robust fundamental performance, multiple normalization toward peer healthcare medtech medians represents severe downside risk.
Align Technology Inc.ALGN
ราคา / มูลค่ายุติธรรม
มูลค่ายุติธรรมUS$121.31Report-date priceUS$147.61
วันที่ประเมิน
ความได้เปรียบในการแข่งขันNarrow
สกอร์การ์ดการลงทุน55 / 100
The Cooper Companies, Inc.COO
ราคา / มูลค่ายุติธรรม
มูลค่ายุติธรรมUS$78.48Report-date priceUS$55.29
วันที่ประเมิน
ความได้เปรียบในการแข่งขันNarrow
สกอร์การ์ดการลงทุน62 / 100
อัตรากำไร
ISRG
Intuitive Surgical Inc.
$143.1B
33.3x
13.2x
33.0x
17.4%
—
VRTX
Vertex Pharmaceuticals Incorporated
$133.3B
26.2x
10.6x
25.0x
23.5%
38.1%
TMO
Thermo Fisher Scientific Inc.
$249.6B
24.5x
5.4x
24.6x
13.5%
18.8%
ALGN
Align Technology Inc.
$10.4B
11.7x
2.5x
10.2x
10.2%
18.2%
COO
The Cooper Companies Inc.
$10.5B
11.8x
2.5x
14.1x
6.8%
20.8%
Integration of advanced compute, sensing, and digital surgical ecosystems
positive
Robotic platforms increasingly leverage onboard processing power and force-sensing technologies to deliver actionable surgical insights, exemplified by da Vinci 5's computing architecture and regular software updates.
Global healthcare reimbursement tightening and centralized tender procurement
negative
Public healthcare systems in Europe and Asia enforce centralized pricing discipline and extended procurement evaluation cycles, requiring tailored value-tier offerings to preserve market access.
Evaluate entry for long-term compounders
At the lower bound of intrinsic value, multiple compression risks are fully absorbed, offering compelling risk-adjusted compounding returns.
